Clinical trial
Safety and Tolerability of Varying Load and Dose of ISIS 301012 in People With…
NCT00216463 · Kastle Therapeutics, LLC, Industry · Completed
Key facts
| NCT number | NCT00216463 |
|---|---|
| Title | Safety and Tolerability of Varying Load and Dose of ISIS 301012 in People With Elevated LDL-cholesterol Levels |
| Official title | A Phase 2, Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Varying Loading and Maintenance Dosing Regimens of ISIS 301012 Administered to Hypercholesterolemic Subjects |
| Lead sponsor | Kastle Therapeutics, LLC, Industry |
| Collaborators | Ionis Pharmaceuticals, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hypercholesterolemia |
| Intervention type | Drug |
| Interventions | ISIS 301012 or Placebo |
| Enrollment | 50 |
| Start date | Aug 1, 2005 |
| Primary completion | Mar 1, 2007 |
| Completion | Aug 1, 2007 |
| First posted | Sep 22, 2005 |
| Last update posted | Aug 3, 2016 |
| Countries | Germany |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: